9 completed. 7 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
| Phase 2 | 3 | Completed 3 |
Follow TA-8995: new trials by email Literature Review of TA-8995 trials Research Report on TA-8995
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease Obicetrapib - Early Alzheimer's Disease | Phase 2 | Completed | NewAmsterdam Pharma | 13 | 2022-01-12 | 2025-01-29 |
| Bioequivalence Study of Capsule and Tablet Formulations of TA-8995 TA-8995 - Dyslipidaemia | Phase 1 | Completed | Xention Ltd | 26 | 2015-07-01 | 2016-01-29 |
| ADME Study in Healthy Male Subjects With TA-8995 TA-8995 - Dyslipidemia | Phase 1 | Completed | Xention Ltd | 6 | 2015-06-01 | 2016-10-03 |
| A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a) TA-8995, Placebo - Elevated Lp(a) | Phase 1 / Phase 2 | Completed | Xention Ltd | 42 | 2014-09-01 | 2015-02-16 |
| Study of the Electrocardiographic Effects of TA-8995 TA-8995, Moxifloxacin, Placebo - Dyslipidaemia | Phase 1 | Completed | Xention Ltd | 136 | 2014-08-01 | 2015-02-16 |
| A Preliminary Drug Drug Interaction Study With TA-8995 TA-8995, Midazolam, Digoxin - Pharmacokinetic Interactions | Phase 1 | Completed | Xention Ltd | 18 | 2014-05-01 | 2016-10-03 |
| TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP) TA-8995, Atorvastatin, Rosuvastatin - Dyslipidemia | Phase 2 | Completed | Xention Ltd | 364 | 2013-08-01 | 2014-08-21 |
| Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects TA-8995, Placebo - Dyslipidemia | Phase 1 | Completed | Tanabe Pharma Corporation | 61 | 2009-08-01 | 2013-06-17 |
| Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 With Single, Escalating Doses in Healthy Subjects TA-8995, Placebo - Dyslipidemia | Phase 1 | Completed | Tanabe Pharma Corporation | 96 | 2008-03-01 | 2013-06-17 |
Dyslipidemias (6) · Alzheimer Disease (1)
Xention Ltd (6) · Tanabe Pharma Corporation (2) · NewAmsterdam Pharma (1)
United Kingdom (5) · Denmark (2) · Netherlands (2) · Germany (1)
Ashley Brooks (3) · Marc Ditmarsch, MD (1) · Steve Warrington, MA MD FRCP FFPM (1) · Werner Weber, MD (1)